Kanghong Pharmaceutical announced that it recently received the “Drug Registration Certificate” for bryprazole tablets issued by the State Drug Administration and approved the registration. The mechanism of action of brypiprazole for the treatment of schizophrenia is unclear. It may be mediated by a combination of serotonin 5-HT1A and dopamine D2 receptor agonist activity and serotonin 5-HT2A receptor antagonist activity. This time, bryprazole tablets were approved for marketing, which has enriched the company's product pipeline.

Kanghong Pharmaceutical announced that it recently received the “Drug Registration Certificate” for bryprazole tablets issued by the State Drug Administration and approved the registration. The mechanism of action of brypiprazole for the treatment of schizophrenia is unclear. It may be mediated by a combination of serotonin 5-HT1A and dopamine D2 receptor agonist activity and serotonin 5-HT2A receptor antagonist activity. This time, bryprazole tablets were approved for marketing, which has enriched the company's product pipeline.